Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple liver scan replace risky heart catheters?

NCT ID NCT07222813

Diagnosis Sponsor: Echosens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a quick, painless liver scan (FibroScan) can accurately detect high central venous pressure in people with heart failure. Currently, doctors use a catheter inserted into the heart to measure this pressure, which carries risks. The study will enroll 149 adults with suspected or diagnosed heart failure who are already scheduled for catheterization. Researchers will compare the liver scan results to the catheter measurements to see if the scan can reliably identify elevated pressure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FibroScan (non-invasive liver stiffness measurement device)
What this could lead to
If successful, this could provide a safe, quick, and needle-free way to check for fluid buildup in heart failure patients, avoiding the risks of invasive catheterization.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The liver stiffness cutoff may not be accurate enough in all patients, and results may not apply to those with liver disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 149 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Have read, understood, and signed the informed consent form (ICF) 2. Be ≥18 years of age at the time of screening 3. Have suspected or diagnosed acute or chronic HF and be scheduled to undergo right-sided cardiac catheterization Exclusion Criteria: 1. Inability to consent 2. Chronic liver disease (self-reported alcohol use \>14 drinks/week in females and \>21 drinks/week in males), positive hepatitis C virus serology, positive hepatitis B surface antigen, autoimmune hepatitis, hemochromatosis, or cholestatic disease) 3. BMI \>40 kg/m2 4. Fontan-type circulation 5. Ascites 6. Heart transplantation 7. Pregnancy, breastfeeding, or intent to become pregnant during the study 8. Intent to donate/bank or retrieve eggs (ova, oocytes) or donate sperm during the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Heart failure - nyha ii - iv

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire (CHU) de Rennes - Hopital de Pontchaillou

    Rennes, Ile Et Vilaine, 35000, France

  • Deutsches Herzzentrum der Charité (DHZC) - Klinik fuer Herz-, Thorax- und Gefaesschirurgie

    Berlin, 13353, Germany

  • Keck Medicine of USC-Norris Healthcare Center - Transplant Clinic

    Los Angeles, California, 90033, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • University of Minnesota

    Minneota, Minnesota, 55455, United States

  • University of Texas Southwestern Medical Center - Clinical Heart and Vascular Center - West Campus Building 3 Location

    Dallas, Texas, 75390, United States

  • Uniwersytet Medyczny im. Piastow Slaskich we Wroclawiu, Instytut Chorob Serca

    Wroclaw, Basse-Silésie, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.